Loading data...
Loading data...
Analyzing the stock…
70
Gathering technical, fundamental, and market data — a few seconds
Health Care · ·
$58.36
▼ $0.13 (-0.2%)
Market data updated: 09/19 03:57 AM
Fundamentals updated: 09/18/2026
News analyzed: 09/19/2026
Market Cap
$14.46B
Day Range
$57.90 - $59.15
52-Week Range
$33.76 - $59.72
Beta
—
Next Earnings
02.11.2026
Support
$49.97
Resistance
$59.72
EXEL is a stock from the Healthcare sector — Pharmaceuticals, biotech, medical devices, and health insurance — less sensitive to economic cycles, but exposed to regulation and FDA approvals.
+44.6% (1Y)
Strengths: 19/28 factors positiveRisk: Medium
This score and all analysis on this page are for informational and educational purposes only and do not constitute investment advice. Read the full disclaimer
Weighted: Technical 25% · Fundamental 20% · Growth 15% · Valuation 15% · News 10% · Quality 10% · Risk 5%
Overall Score
🟡 Mixed
Technical Trend
🟢 Bullish
Insiders
🔴 Bearish
Computed directly from the same signals behind the score above — not AI-generated.
Biggest positive driver
Earnings per share (EPS) growth
Earnings per share (EPS) growth: 58.0%
Growth
Biggest negative driver
Parabolic SAR
Price is below the SAR point — downtrend
Technical
What to watch next
When today echoes the past.
NO RELIABLE ECHO FOUND
Only 2 historical analog(s) found after removing overlapping dates — too few for a statistically meaningful comparison.
Historical matches considered: 2
TIME ECHO identifies historical situations that resemble the current market state. Historical outcomes are not guarantees of future performance. Similarity does not imply causation, and results may change as new data becomes available.
🗓️ What Changed This Week
as of 09/10/202668
This Week
71
7D Ago
↓ -3
Weakening
Technical
77
7D Ago: 87
↓ -10
Fundamental
79
7D Ago: 79
→ 0
Growth
76
7D Ago: 76
→ 0
Valuation
50
7D Ago: 50
→ 0
News
56
7D Ago: 56
→ 0
Quality
58
7D Ago: 58
→ 0
Risk
56
7D Ago: 56
→ 0
Biggest Declines
📊 Score History
68
Today
—
30D
—
90D
—
1Y
🕰️ Signal Timeline
What StockIQ actually saw for this stock, and what happened after each signal — real data, not a forecast.
today · $58.42
Evidence: FOMO score jumped from 3 to 28 day-over-day
What happened after
Still awaiting outcome
🐂🐻 Investment Thesis
🐂 Bull Case
⚖️ Base Case
68 / 100
🐻 Bear Case
🔍 What Could Prove This Wrong
This isn't a price-direction forecast — just a synthesis of real, already-computed data, and future conditions that could change the picture.
🕰️ StockIQ Time Machine
What did StockIQ know — and when? Pick a date from the real accumulated history.
As of September 4, 2026
Then
71
$59.13
Now
68
$58.36
What happened since
Signals detected by this date
No signals detected by this date
🧬 STOCK DNA
This stock's profile across 8 real dimensions — a research tool, not a recommendation
Growth
76
Quality
58
Value
50
Momentum
77
Risk
56
Sentiment
56
Fundamental
79
Institutional
0
Stocks with a similar DNA right now
This stock hasn't been analyzed by StockIQAI's movement engine yet — coverage is still expanding. Check back soon.
Recent media coverage of Exelixis, Inc. highlights its stock performance and investor interest, particularly after a rebound following second-quarter earnings. The company’s shares have surged 13.3% since its last earnings report, breaking out to all-time highs and entering a "buy zone" according to financial analysts. Exelixis, a biotech firm specializing in cancer treatments, is also noted for its FDA-approved medications and upcoming investor conferences in September, where management will participate in fireside chats.
AI summary based on English-language news sources only — not investment advice.
Everyone's writing about Exelixis, Inc.. News trend score: 56. Reason: 9 of the last 20 articles are positive, versus 8 negative.
News trend analysis is based on article sentiment only, and is not investment advice or financial counsel. Read the full disclaimer
🌡️ Emotional Temperature
24
🎯 Conviction (vs. Emotion)
41
Psychology
58
Fundamentals
79
Technical
77
Valuation
50
The price is holding at a real, documented historical support/resistance level (a 50-day high or low).
The stock is moving in lockstep with its peers at the same intensity, rather than on its own data.
Price, volume, and sentiment accelerating together — a sign investors are chasing the price, not just following it.
Extreme momentum, price far above its moving average, and a large premium over fair value.
The price rise has far outpaced the actual improvement in fundamental data.
Price (3M)
+13%
Market Narrative
48
Fundamental Reality
41
Narrative Gap
+7
🧠 StockIQ Psychologist
The dominant anchoring behavior reflects traders’ fixation on the 1.9% resistance gap, a common bias when price nears a psychological hurdle. FOMO and herding signals are muted despite positive momentum, implying selective participation rather than herd-driven moves. The narrative gap (14 points) hints at a disconnect where optimism (e.g., sentiment, momentum) slightly exceeds tangible fundamentals. The key question: will traders break anchor resistance or pivot if momentum stalls?
Updated: 09/09/2026, 04:59 AM
What could change this?
👥 What the crowd believes
"Exelixis is Friday's IBD Stock Of The Day. Shares have recovered from a post second-quarter drop"
"Exelixis holds third place in IBD's profitable biotech group... The company has cancer medications approved by the U.S. Food and Drug Administration"
"Exelixis, Inc. announced management will participate in fireside chats at upcoming investor conferences in September"
🧠 Market Brain events driving this
📈 11D Investor Psychology
Signal classification confidence: High (confidence in the behavioral read, not a price prediction). Describes observable market behavior, not what any individual investor thinks, and is not a buy/sell signal.
🏛️ Investor DNA — Historical Investors
A Historical Strategy Simulation: assuming each investor follows their documented principles, how would they rate this stock today? This is not a prediction of what they would actually do.
🟢 Best match
Walter Bagehot — 100/100
🔴 Weakest match
Samuel Armstrong Nelson — 17/100
🗣️ Why do they disagree?
The stark divide in verdicts for EXEL reflects deep methodological contrasts between growth-focused and defensive investors. At the top, Walter Bagehot’s near-perfect score highlights the stock’s liquidity resilience, aligning with his credit-market pragmatism, while Peter Lynch and Philip Fisher’s high scores suggest a strong growth story and exceptional quality—both prioritizing earnings potential over traditional valuation. Meanwhile, the middle tier—including Morgan Housel and Howard Marks—balances optimism with caution, noting the stock’s compounding potential but warning of elevated expectations. On the opposite end, Benjamin Graham and the efficient-market camp dismiss it outright, with Graham’s defensive framework rejecting its volatility and the Efficient Market Hypothesis questioning its stock-picking edge. Samuel Nelson’s near-zero score underscores a cyclical overbought warning, while Jack Schwager’s low score reflects a lack of technical setup. The debate thus hinges on whether EXEL’s growth justifies risk (for Lynch, Fisher, or Bagehot) or if its valuation and market positioning make it a speculative gamble (for Graham, Marks, or Nelson).
Walter Bagehot
Lombard Street (1873)
🟢 100
Strong liquidity — would likely survive a real credit squeeze
Key question
Does this company have enough liquidity to survive real stress?
Fact → Principle → Simulation
Peter Lynch
One Up on Wall Street (1989)
🟢 84
Growth candidate — the price hasn't caught up to the growth
Key question
Is the growth worth the price?
Fact → Principle → Simulation
Philip Fisher
Common Stocks and Uncommon Profits (1958)
🟢 75
Exceptional company quality by Fisher's standards
Key question
How exceptional is this business, really?
Fact → Principle → Simulation
Thorstein Veblen
The Theory of Business Enterprise (1904)
🟢 71
Growth appears aligned with real value creation
Key question
Is management building real value, or just building itself?
Fact → Principle → Simulation
Charles Mackay
Extraordinary Popular Delusions and the Madness of Crowds (1841)
🟢 69
Some signs of crowd excitement building
Key question
Am I being swept along with the crowd, or thinking for myself?
Fact → Principle → Simulation
Howard Marks
The Most Important Thing (2011) / Mastering the Market Cycle (2018)
🟢 67
Risk appears reasonably priced — no obvious cycle-timing red flag
Key question
What is the market probably misunderstanding about the risk here?
Fact → Principle → Simulation
Morgan Housel
The Psychology of Money (2020)
🟢 67
The kind of quiet compounder a patient holder could actually stick with
Key question
Could I live with this volatility long enough for compounding to actually work?
Fact → Principle → Simulation
Gerald M. Loeb
The Battle for Investment Survival (1935)
🟡 62
Moderate risk to capital
Key question
How much capital could I lose here if I'm wrong?
Fact → Principle → Simulation
Jesse Livermore
Reminiscences of a Stock Operator (1923) / How to Trade in Stocks (1940)
🟡 57
No clear trend — Livermore preferred to stay out of this
Key question
What is the price telling me right now?
Fact → Principle → Simulation
Howard Marks (Market Cycle)
Mastering the Market Cycle (2018)
🟡 43
Somewhere in the middle of the cycle
Key question
Where are we in the cycle right now — near a hot extreme, or a cold one?
Fact → Principle → Simulation
Edgar Lawrence Smith
Common Stocks as Long-Term Investments (1924)
🟡 42
Reasonable but not a clear long-term holding
Key question
Is this a stock I'd be happy to hold and forget about for a decade?
Fact → Principle → Simulation
Burton Malkiel & John Bogle
A Random Walk Down Wall Street (1973) / The Little Book of Common Sense Investing (2007)
🟡 41
Mixed case — the evidence for picking this stock over an index is not strong
Key question
Do I actually have an edge here, or do I just think I do?
Fact → Principle → Simulation
Benjamin Graham
Security Analysis (1934) / The Intelligent Investor (1949)
🟡 40
Fails most of Graham's defensive criteria
Key question
Where is my margin of safety?
Fact → Principle → Simulation
Benjamin Graham (Enterprising Investor)
The Intelligent Investor (1949) — the Enterprising Investor chapters
🔴 31
Not statistically cheap enough for the Enterprising Investor's looser safety bar
Key question
Is the stock statistically cheap enough to justify the extra risk?
Fact → Principle → Simulation
Jack Schwager
Market Wizards (1989)
🔴 21
No real setup here — the discipline Schwager's wizards shared would say stay out
Key question
What's the risk/reward here, and where is my exit point?
Fact → Principle → Simulation
Samuel Armstrong Nelson
The ABC of Stock Speculation (1903)
🔴 17
Cycle looks stretched toward overbought
Key question
Is the price overextended, or is there still room to move?
Fact → Principle → Simulation
Based on the last 279 trading days, calculated from real price data. Click an indicator for details and a chart.
🟢 Most indicators support an uptrend (8 bullish · 2 bearish · 1 neutral)
A market-structure read based purely on real price and volume data — not full classic Wyckoff schematic identification (Phase A-E), but a quantitative analysis of what can reliably be computed: trading ranges, "effort vs. result", volume within the range, and Spring/Upthrust detection.
A pattern consistent with an early/mid distribution phase — a trading range after an advance with declining volume.
Medium confidence
$49.97
Range Bottom
$59.72
Range Top
50
Trading Days in Range
The Wyckoff Method, developed by Richard Wyckoff in the early 20th century, reads the balance of supply and demand through price and volume, based on the premise that large investors ("smart money") quietly accumulate shares before rallies and quietly distribute them before declines. The read here is based solely on real price and volume data — full, precise identification of classic Wyckoff patterns (such as Phases A-E) requires human chart-reading experience and judgment, so this is an approximate algorithmic read, not a substitute for professional analysis. This should not be considered investment advice.
Gross Margin
96.4%
Operating Margin
37.6%
Net Margin
33.7%
EBITDA Margin
38.8%
ROE
36.2%
ROA
27.5%
ROIC
—
EPS
$2.88
Cash
$482.49M
Total Debt
—
Current Ratio
3.56
Debt/Equity
—
How is Fair Value calculated? →
Current Price
$58.36
Estimated Fair Value (DCF)
$61.89
Model estimate — not a price target. Highly sensitive to growth/discount-rate assumptions.
Gap
+6.1%
🟢 Appears cheap relative to estimated value
Year 1 Growth Rate
13.0%
Discount Rate (WACC)
9.0%
Terminal Growth Rate
2.5%
Projection Years
5
| Year | Growth Rate | Projected FCF | Present Value |
|---|---|---|---|
| 1 | 13.0% | $989.93M | $908.19M |
| 2 | 10.4% | $1.09B | $919.81M |
| 3 | 7.8% | $1.18B | $909.38M |
| 4 | 5.1% | $1.24B | $877.10M |
| 5 | 2.5% | $1.27B | $824.80M |
Base FCF (last actual year)
$875.84M
Terminal Value
$20.01B
Present Value of Terminal Value
$13.01B
Enterprise Value
$17.45B
Net Debt
$0
Equity Value
$17.45B
*The DCF model is an estimate based on assumptions — not a guaranteed forecast. You can change the assumptions to examine different scenarios.
Book Value per Share
$7.67
Tangible Book Value per Share (Tangible NAV)
$7.44
Sentiment based on basic keywords (not AI) — 9 positive, 3 neutral, 8 negative out of the last 20 articles.
Yahoo · 17.9.2026
Yahoo · 17.9.2026
SeekingAlpha · 15.9.2026
Yahoo · 15.9.2026
MarketBeat · 15.9.2026
SeekingAlpha · 14.9.2026
MarketBeat · 14.9.2026
Yahoo · 14.9.2026
SeekingAlpha · 14.9.2026
Yahoo · 11.9.2026
Stocktwits · 11.9.2026
Investor's Business Daily · 11.9.2026
MT Newswires · 11.9.2026
MT Newswires · 11.9.2026
Yahoo · 11.9.2026
Benzinga · 11.9.2026
InvestorsHub · 11.9.2026
Yahoo · 11.9.2026
MT Newswires · 11.9.2026
MT Newswires · 11.9.2026
Exelixis, Inc. (EXEL) currently has a StockIQ AI score of 68/100, rated "Moderate". The score is a weighted average across up to 7 categories (technical, fundamental, growth, fair value, news, quality, risk), based on real data only.
EXEL currently scores 68/100 (Moderate) across the categories we measure. StockIQ doesn't give buy/sell recommendations — use this as one data point in your own research, not as investment advice.
Per StockIQ's DCF model, EXEL's estimated fair value is $61.89, which is 6.1% above the current price of $58.36. This is one valuation model among several signals in the fair-value category, not a price target.
EXEL's technical score is 77/100, which currently reads as bullish — based on real price/volume signals (moving averages, RSI, MACD, and more), not a prediction of what happens next.
Based on the real signals StockIQ computed: Earnings per share (EPS) growth: 58.0%; Free cash flow growth: 30.4%; Net income growth: 50.1%.
Based on the real signals StockIQ computed: Price is below the SAR point — downtrend; %K 80.4 — overbought.
StockIQ has no recorded dividend payment history for EXEL.
Real transactions by officers and insiders, as reported to the SEC on Form 4 — 0 purchases and 6 sales out of the last 25 filings.
| Name | Transaction Type | Date | Shares | Change | Price |
|---|---|---|---|---|---|
| Beckerle Mary C | Open Market Sale | 10.8.2026 | 16,079 | -9,812 | $53.66 |
| Beckerle Mary C | Open Market Sale | 10.8.2026 | 9,812 | -9,812 | $53.66 |
| WYSZOMIERSKI JACK L | Open Market Sale | 1.6.2026 | 3,925 | -3,925 | $50.55 |
| Eckhardt Sue Gail | Open Market Sale | 1.6.2026 | 9,812 | -9,812 | $50.14 |
| WYSZOMIERSKI JACK L | Open Market Sale | 1.6.2026 | 284,384 | -3,925 | $50.55 |
| Eckhardt Sue Gail | Open Market Sale | 1.6.2026 | 16,079 | -9,812 | $50.14 |
| JOHNSON DAVID EDWARD | Grant/Award from Employer | 27.5.2026 | 19,133 | +19,133 | — |
| POSTE GEORGE | Grant/Award from Employer | 27.5.2026 | 8,367 | +8,367 | — |
| Oliver Bob | Grant/Award from Employer | 27.5.2026 | 8,367 | +8,367 | — |
| WYSZOMIERSKI JACK L | Grant/Award from Employer | 27.5.2026 | 8,367 | +8,367 | — |
| Beckerle Mary C | Grant/Award from Employer | 27.5.2026 | 8,367 | +8,367 | — |
| Eckhardt Sue Gail | Grant/Award from Employer | 27.5.2026 | 8,367 | +8,367 | — |
| Smith Julie | Grant/Award from Employer | 27.5.2026 | 8,367 | +8,367 | — |
| Freire Maria C | Grant/Award from Employer | 27.5.2026 | 8,367 | +8,367 | — |
| Heyman Tomas J. | Grant/Award from Employer | 27.5.2026 | 8,367 | +8,367 | — |
| PAPADOPOULOS STELIOS | Grant/Award from Employer | 27.5.2026 | 8,367 | +8,367 | — |
| WYSZOMIERSKI JACK L | Grant/Award from Employer | 27.5.2026 | 288,309 | +8,367 | — |
| POSTE GEORGE | Grant/Award from Employer | 27.5.2026 | 127,199 | +8,367 | — |
| PAPADOPOULOS STELIOS | Grant/Award from Employer | 27.5.2026 | 1,197,595 | +8,367 | — |
| Beckerle Mary C | Grant/Award from Employer | 27.5.2026 | 25,891 | +8,367 | — |
| Freire Maria C | Grant/Award from Employer | 27.5.2026 | 109,186 | +8,367 | — |
| Smith Julie | Grant/Award from Employer | 27.5.2026 | 28,957 | +8,367 | — |
| Oliver Bob | Grant/Award from Employer | 27.5.2026 | 29,487 | +8,367 | — |
| Caligan Partners LP | Grant/Award from Employer | 27.5.2026 | 19,133 | +19,133 | — |
| Heyman Tomas J. | Grant/Award from Employer | 27.5.2026 | 50,649 | +8,367 | — |
Official FINRA data — the number of shares open in short positions, plus daily short-sale activity.
28,656,285 shares short as of 2026-08-31 · vs. 28,749,664 on 2026-07-31
Official biweekly report (FINRA Rule 4560) — no real higher-frequency data exists for this metric.
62.7% of trading volume this week was short selling, vs. 62.8% the prior week
Based on daily short-sale volume (Reg SHO) — a different metric from the open short interest above: this is daily trading volume, not an open position, so it updates weekly rather than biweekly.
Full breakdown of every data type and its source: Data Sources · Methodology